AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04155619 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No change in meal timing
Description: Participants will eat within an ≥11-hour daily period (no change in meal timing habits).
Study NCT04155619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No change in meal timing
Description: Participants will eat within an ≥11-hour daily period (no change in meal timing habits).
Study NCT04155619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No change in light exposure
Description: Participants will not change their light exposure habits.
Study NCT04155619 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No change in light exposure
Description: Participants will not change their light exposure habits.
Study NCT04155619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Time-Restricted Feeding
Description: Participants will eat within an 8-hour daily period early in the day, starting within 2 hours of waking up.
Study NCT04155619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Timed Light Therapy
Description: Participants will use bright light therapy for 60 minutes between 6 am - 3 pm, blue light-blocking glasses for one hour before bedtime, and blackout curtains at night.
Study NCT06089837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC5026 oral tablet
Description: 2 sequential cohorts of 8 subjects randomly assigned to receive multiple ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort) for 7 consecutive days.~Oral doses of EC5026 tested in each cohort:~4 mg loading dose on Day 1 / 2 mg Maintenance dose on Days 2-7 (Cohort 1) 8 mg loading dose on Day 1 / 4 mg Maintenance dose on Days 2-7 (Cohort 2)
Study NCT06089837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: 2 sequential cohorts of 8 subjects randomly assigned to receive multiple ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort) for 7 consecutive days. Subject assigned to the Placebo Arm will receive 7 days of matching placebo oral tablets in each Cohort.
Study NCT05316584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote monitoring
Description: See prior description of the intervention.
Study NCT06651281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tulisokibart
Description: Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered subcutaneously
Study NCT06651281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to tulisokibart
Description: Placebo matching SC tulisokibart
Study NCT06497218 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blinklab diagnostic device
Description: Blinklab is a non-invasive diagnostic device for Autism Spectrum Disorder
Study NCT06436742 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-119
Description: Intravenous infusion of ARGX-119
Study NCT06436742 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of placebo
Study NCT06414395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precedex (Dexmedetomidine) 200 MCG in 2 ML Injection
Description: The Effects of Different Loading Doses of Dexmedetomidine on The Bispectral Index-Guided Propofol Sedation in Patients Undergoing Advanced Upper Gastrointestinal Endoscopic Procedures: A Randomized Control Study
Study NCT06414395 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: C group: Patients received saline infusion over 10 minutes
Description: the group will receive normal saline infusion over 10 minutes.
Study NCT05821634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized intervention condition: Cognitive behavioral therapy skills
Description: An 11-session cognitive behavioral therapy (CBT) skills based intervention will be delivered to participants randomized to the personalized intervention. Influential constructs will be identified using the person specific digital phenotyping model, targeted using CBT skills, and tracked across sessions.
Study NCT05821634 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic control condition: Cognitive behavioral therapy skills
Description: Participants randomized to this condition will receive an 11-session CBT skills based treatment targeting a non-personalized construct selected from the person-specific digital phenotyping model.
Study NCT05821634 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tracking control condition: Supportive counseling
Description: Participants randomized to this condition will receive 11 supportive counseling sessions that are non-directive in nature (providing support and validation for non-acute weekly stressors). Participants will continue digital phenotyping, controlling for the effect of counseling and digital phenotyping.
Study NCT05383365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suboccipital Myofascial Release(MFR) with sham Deep Neck Flexor(DNF)exercise
Description: The treatment includes Suboccipital MFR in the supine position.The therapist places the supinated forearm on the bed and positions the tips of the middle three fingers inferior to the occiput bone and the head is supported by the thenar eminences.The therapist will develop a line of tension through the suboccipital tissues by supinating the forearms and pulling apart two hands from each other;Then, for the second level in the first position of hands,pressure is applied to the anterior and superior direction.The pressure is held and increased until the therapist feels the decrease of muscle tone.These techniques last 10 minutes.~Another intervention in this group is the sham DNF exercise with a Pressure Biofeedback Unit(PBU).Considering that minimum detective change with PBU is 15 mmHg; After placing the airbag of PBU under the occiput bone in the supine position and inflating it to a base pressure of 11 mmHg,the participant will increase the pressure to 12 mmHg by nodding action.
Study NCT05383365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Neck Flexor(DNF)exercise with sham Suboccipital Myofascial Release(MFR)
Description: The treatments include the DNF exercise with a PBU. The treatment is performed in the supine position and the airbag is placed under the occiput bone and is inflated to a base pressure of 20 mmHg. The participant will increase and hold the pressure to a special point by nodding action. The exercise is repeated for 3 sets, in each set 2 mm Hg is added to the pressure. The pressure will be increased from 22 to 32 mm Hg during 4-week of treatment, and each goal is held for 10 seconds and repeated 10 times. There will be 5 sec of rest between each repetition and 2 min of rest between each set.~Another intervention in this group is sham MFR. The therapist's hands will be placed only inferior to the occipital bone and a superficial touch is applied without any upward or lateral pressure. sham treatment in this group, like the opposite group, lasts 10 minutes.
Study NCT06061003 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Anatomical Education with Fractured Bone Models
Description: Participants will undergo a 2-hour training session, consisting of 60 minutes of theory and 60 minutes of practice. The theoretical lesson, supported by 2D images illustrating wrist anatomy, types of fractures, and rehabilitation based on fracture type, will be simultaneously delivered to both groups. Following this, the practical group will receive a 60-minute hands-on session using 3D-printed digital models of radius and ulna fractures. These training sessions will be scheduled in the morning hours, on a day when students have no other classes between 9 am and 12 pm, to minimize mental fatigue and exhaustion. In the practical session, anatomical structures, their relationships, and arrangements will be demonstrated to the practice group using a model of a fractured wrist.
Study NCT06061003 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Anatomical Education with Standard Bone Models
Description: Participants will undergo a 2-hour training session, consisting of 60 minutes of theory and 60 minutes of practice. The theoretical lesson, supported by 2D images illustrating wrist anatomy, types of fractures, and rehabilitation based on fracture type, will be simultaneously delivered to both groups. Following this, the practical group will receive a 60-minute hands-on session using 3D-printed digital models of radius and ulna fractures. These training sessions will be scheduled in the morning hours, on a day when students have no other classes between 9 am and 12 pm, to minimize mental fatigue and exhaustion. The control group will receive the same practical session using a standard anatomical model.
Study NCT05313568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: static stretching
Description: The stretch will be done by placing both feet on a raised platform, lowering the heel off the platform without touching the ground, and held in this position to perform a static stretch. They will perform 5 repetitions, 15 seconds of rest and 1 minute of stretching.
Study NCT05313568 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: static stretching
Description: The stretch will be done by placing both feet on a raised platform, lowering the heel off the platform without touching the ground, and held in this position to perform a static stretch. They will perform 5 repetitions, 15 seconds of rest and 1 minute of stretching.
Study NCT05313568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self massage
Description: In addition to the self-stretching application, plantar self-massage will be applied. Plantar self massage will be shown to the participants by the physiotherapist with a 7 cm spiky massage ball. Then, participants will be asked to self-massage the plantar sole of the foot for 5 minutes with a 7 cm spiky massage ball.
Study NCT05313568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Stimulation
Description: In addition to the self-stretching application, manual stimulation will be applied.~Manual protocol:~A) Pressure will be applied in each interdigital space and on the longitudinal arch with shear in the longitudinal direction (5 repetitions of 10 seconds each).~B) Pressure with transverse shear on the metatarsal heads (5 repetitions of 5 seconds each) C) Static pressure will be applied to the first and fifth metatarsal head, center of the midfoot, and heel (5 repetitions per 10-second period each).
Study NCT04833894 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod IV
Description: Intravenous infusion of Efgartigimod
Study NCT06646822 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: observational study
Study NCT04955834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin degludec injection
Description: long-acting insulin
Study NCT04955834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tresiba®
Description: long-acting insulin
Study NCT05254639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DONEPEZIL
Description: 5 mg daily for 4 weeks + 10 mg daily for 12 weeks according to tolerance or efficacy
Study NCT05254639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: 5 mg daily for 4 weeks + 10 mg daily for 12 weeks according to tolerance or efficacy
Study NCT04994496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two-week web-based self-help intervention based on principles of positive psychology
Description: The web-based self-help intervention consists of 14 exercises based on the following positive psychology domains: personal strengths, pleasure, gratitude, engagement (flow, mindfulness) and positive relationships.~The (partly interactive) exercises are created to be implemented by the participants themselves without support of a therapist.~Before starting the intervention, the participants are told that they will receive a daily email with an instruction for a short exercise over the period of two weeks. The participants are instructed to complete the exercises every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)
Study NCT04994496 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Two-week web-based text messages containing fun facts
Description: The web-based sham intervention consists of 14 text messages containing random interesting facts (fun facts).~Before starting the sham intervention, the participants are told that they will receive a daily email with a text message to read every over the period of two weeks. The participants are instructed to read these text messages every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)
Study NCT06053034 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Solio alpha cure plus
Description: The SOLIO Alfa Cure Plus is the only home-use device with FDA clearance that uses the proprietary synergy of three energy sources (IR, RF, and LLLT), and this study aims to assess the SOLIO Alfa Cure Plus's efficiency in providing pain relief. This technology is the first noninvasive and patented home RF device. SOLIO Alfa Cure Plus uses continuous RF, the internal controller reduces the RF power while reaching the treatment temperature of 39- 42 Celsius.The SOLIO Alfa Cure Plus Device is a round device equipped with a strap for hand holding, it is to be used while connected to a socket. The device is used by an assistant (usually a family member) on the participant's back for 20 minutes while moving it around in circles on the lower back.
Study NCT06053034 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Solio alpha cure plus
Description: The SOLIO Alfa Cure Plus is the only home-use device with FDA clearance that uses the proprietary synergy of three energy sources (IR, RF, and LLLT), and this study aims to assess the SOLIO Alfa Cure Plus's efficiency in providing pain relief. This technology is the first noninvasive and patented home RF device. SOLIO Alfa Cure Plus uses continuous RF, the internal controller reduces the RF power while reaching the treatment temperature of 39- 42 Celsius.The SOLIO Alfa Cure Plus Device is a round device equipped with a strap for hand holding, it is to be used while connected to a socket. The device is used by an assistant (usually a family member) on the participant's back for 20 minutes while moving it around in circles on the lower back.
Study NCT05048849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901(S protein with adjuvant)
Description: Approximately 500 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
Study NCT05169970 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Patients with a low or intermediate risk Decipher score will receive radiation targeting the seminal prostate and seminal vesicles to a dose of 40 Gy in 5 fractions delivered every other day.
Study NCT05169970 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Patients with high risk Decipher scores will receive radiation targeting the prostate and seminal vesicles to a dose of 40 Gy in 5 fractions with a simultaneous integrated boost to 45 Gy of any dominant intraprostatic lesion as well as radiation to the pelvic lymph nodes to a dose of 25 Gy in 5 fractions delivered every other day.
Study NCT05567796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cagrilintide
Description: Cagrilintide will be administered subcutaneously.
Study NCT05567796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Cagrilintide will be administered subcutaneously.
Study NCT05567796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will recieve semaglutide subcutaneously.
Study NCT05567796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Participants will recieve semaglutide subcutaneously.
Study NCT05567796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cagrilintide
Description: Participants will receive placebo matched to cagrilintide.
Study NCT05567796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo cagrilintide
Description: Participants will receive placebo matched to cagrilintide.
Study NCT05567796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo semaglutide
Description: Participants will receive placebo matched to semaglutide.
Study NCT05567796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo semaglutide
Description: Participants will receive placebo matched to semaglutide.
Study NCT05377905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microneedle Array Doxorubicin (MNA-D)
Description: The Microneedle array patch is loaded/prepared with a total dose of 50 micrograms of Doxorubicin and is applied to a single selected cSCC remnant for a period of 20 minutes for a total of 4 weekly applications
Study NCT06652672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Organ-sparing surgery
Description: Endoscopy-assisted laparoscopic/robotic wedge resection and sentinel lymph node biopsy using submucosal injection of ICG.
Study NCT06652672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care segmental resection
Description: Standard of care segmental resection of the affected part of the colon including removal of regional lymph nodes.
Study NCT06661876 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 5 Gray Whole Heart external beam radiotherapy
Description: EBRT will be delivered with photon energies restricted to 6 Megavoltage (MV) using intensity modulated radiotherapy (IMRT) or Volumetric modulated arc therapy (VMAT). Patients will be treated with a single fraction treatment up to a dose of 5Gy prescribed to the 95% PTV-encompassing isodose line (PTVD95% ≥5Gy). The near-maximum dose is limited to 5.35Gy (PTV D2% ≤ 5.35Gy). The treatment can be performed both as an inpatient or outpatient procedure.
Study NCT06003582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Parent Support
Description: Therapeutic Intervention
Study NCT04945239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Amplification of Positivity Training (6 Sessions)
Description: 6 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
Study NCT04945239 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management Training (6 Sessions)
Description: 6 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for activity exercises designed to decrease stress.
Study NCT06181721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnipod 5 Automated Glucose Control System
Description: The Omnipod 5 Automated Glucose Control System will provide automated insulin delivery
Study NCT06674681 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HPV Self-Collection
Description: HPV self-collection program for in-clinic and mailed cervical cancer screening.
Study NCT05819931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical In-Exsufflator treatment
Description: The Mechanical In-Exsufflator (MIE) is a device that alternately inhales and exhales air and amplifies the respiratory cycles in flow and pressure. 15 breathing cycles (about 3 minutes) are recommended each day.~Patients will practice the MIE daily independently and/or carried out by his physiotherapist (PT) during PT sessions.~The MIE is prescribed by the neurologist or pulmonologist and is covered by social security in France. It is gifted by an external service provider.~The Peak-Flow Cough is considered as the standardized score retaining the best of 3 consecutive measurements by Peak-Flow, a small portable device for personal use, which measures the maximum expiratory flow reached by the patient at the moment when the breath is most powerful.~The patient is his own control. At baseline, the patient will be treated as usual. He will be asked to read the Peak-Flow Cough measures. The PT will also perform the Peak flow measurement at each patient visit.
Study NCT06684288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Access flap surgery
Description: Granulation tissue attached to the alveolar bone was excised to ensure complete access and optimal visibility of the root surfaces. In addition, instrumentation was performed using a combination of ultrasonic and hand instruments, and no alveolar bone modification was undertaken during the flap procedure. Subsequently, the mucoperiosteal flap was repositioned and primarily closed with proximal simple sutures employing monofilament suture material (5/0 Propilen, Dogsan, Türkiye). Patients were given post-operative recommendations; however, no medication was prescribed.
Study NCT04959890 — intervention group
Intervention type: GENETIC
Intervention: Strimvelis
Description: This non-interventional, retrospective, methodology study will use peripheral blood and bone marrow samples previously taken from subjects treated with gRV-GT. The study does not require subjects to undergo any further treatment, intervention or blood withdrawal. Eligible samples will be shipped to a central laboratory and will undergo DNA extraction prior to S-EPTS/LM-PCR analysis. Each analysis run will include a control DNA sample and up to four subject samples. Each sample will be analysed in triplicate.
Study NCT06761664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platysma Exercise Group
Description: The participants in this group will perform a platysma exercise for 7 days following third molar extraction surgery.
Study NCT06761664 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (Standard treatment)
Description: Participants in this group will receive routine treatment following third molar extraction.